![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Checkpoint Licenses Cancer Drugs from Teva
Checkpoint Licenses Cancer Drugs from Teva
January 13, 2016
Biotech company Checkpoint Therapeutics has reached an agreement to license from Teva worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug.
The prodrug, CEP-9722, is designed for treatment of solid tumors and is a small molecule selective inhibitor of the PARP-1 and PARP-2 enzymes. Checkpoint will develop the biologic as a monotherapy and in combination with other anti-cancer agents.
Financial terms of the agreement were not disclosed.
Upcoming Events
-
21Oct